Free tool
Cell therapy stocks
We cover 48 companies grouped under the Cell therapy theme. The median market value in the group is $139.33M. Across the group, the median move over the past trading day is +2.35%. 50% of the 48 with a 200-day average trade above it. Price change over the past year runs from −85.0% to +132.6% across the middle 80 percent of the group, with a median of −10.2%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
48 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $4.14B | Mid cap | −38.44% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.82B | Mid cap | +233.60% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +9.42% |
| VCEL | Vericel Corporation | $2.21B | Mid cap | +20.76% |
| BLFS | BioLife Solutions, Inc. | $1.82B | Small cap | +45.11% |
| VOR | Vor Biopharma Inc. | $1.30B | Small cap | −41.72% |
| SANA | Sana Biotechnology, Inc. | $1.23B | Small cap | +22.39% |
| IMMX | Immix Biopharma, Inc. | $968.90M | Small cap | +589.05% |
| CYRX | Cryoport, Inc. | $846.85M | Small cap | +89.78% |
| ALLO | Allogene Therapeutics, Inc. | $749.72M | Small cap | +87.07% |
| PROK | ProKidney Corp. | $690.59M | Small cap | −26.38% |
| AUTL | Autolus Therapeutics plc | $649.44M | Small cap | +52.50% |
| ARTV | Artiva Biotherapeutics, Inc. | $575.44M | Small cap | +317.38% |
| KYTX | Kyverna Therapeutics, Inc. | $546.70M | Small cap | +132.02% |
| CABA | Cabaletta Bio, Inc. | $545.94M | Small cap | +102.52% |
| CAPR | Capricor Therapeutics, Inc. | $481.97M | Small cap | +25.61% |
| IPSC | Century Therapeutics, Inc. | $392.93M | Small cap | +324.66% |
| LYEL | Lyell Immunopharma, Inc. | $379.58M | Small cap | +41.20% |
| CLLS | Cellectis S.A. | $344.40M | Small cap | +27.14% |
| FATE | Fate Therapeutics, Inc. Common Stock | $305.54M | Small cap | +133.94% |
| RNAC | Cartesian Therapeutics, Inc. | $304.37M | Small cap | −7.73% |
| LCTX | Lineage Cell Therapeutics, Inc. | $275.67M | Small cap | −3.42% |
| NKTX | Nkarta, Inc. | $194.10M | Small cap | +23.18% |
| MXCT | MaxCyte, Inc. | $139.33M | Small cap | −2.88% |
| ATRA | Atara Biotherapeutics, Inc. | $98.77M | Micro cap | −19.61% |
| ACET | Adicet Bio, Inc. | $84.25M | Micro cap | −20.89% |
| INKT | MiNK Therapeutics, Inc. | $60.32M | Micro cap | −21.89% |
| ALPS | Alps Group Inc | $52.42M | Micro cap | −87.70% |
| TCRX | TScan Therapeutics, Inc. | $51.87M | Micro cap | −58.23% |
| TVGN | Tevogen Inc. | $44.34M | Micro cap | −84.85% |
| DTSQ | DT Cloud Star Acquisition Corporation | $41.39M | Micro cap | +8.42% |
| CCEL | Cryo-Cell International, Inc. | $34.67M | Micro cap | −0.92% |
| ESLA | Estrella Immunopharma, Inc. | $31.97M | Micro cap | −24.41% |
| SVA.TO | Sernova Biotherapeutics Inc | $30.03M | Micro cap | −38.89% |
| LGVN | Longeveron Inc. | $21.68M | Micro cap | −12.71% |
| NCEL | NewcelX Ltd. | $19.83M | Micro cap | −85.80% |
| PLUR | Pluri Inc. | $17.91M | Micro cap | −71.43% |
| BCDA | BioCardia, Inc. | $17.11M | Micro cap | −42.05% |
| SNTI | Senti Biosciences Holdings, Inc. | $12.17M | Micro cap | −75.42% |
| INAB | IN8bio, Inc. | $11.53M | Micro cap | −46.58% |
| GDTC | CytoMed Therapeutics Limited | $11.06M | Micro cap | −52.59% |
| FBLG | FibroBiologics, Inc. | $9.32M | Micro cap | −88.54% |
| CELZ | Creative Medical Technology Holdings, Inc. | $7.98M | Micro cap | −61.19% |
| ERNA | Ernexa Therapeutics Inc. | $5.87M | Micro cap | −86.22% |
| PMCB | PharmaCyte Biotech, Inc. | $5.79M | Micro cap | −48.78% |
| BRTX | BioRestorative Therapies, Inc. | $5.67M | Micro cap | −85.26% |
| MBIO | Mustang Bio, Inc. | $4.18M | Micro cap | −64.16% |
| DTSQU | DT Cloud Star Acquisition Corporation | — | Small cap | +9.95% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.